Risk from fluctuations in interest rates, foreign exchange rates and securities prices
First written in FY2017-Q3. 15 of 27 entries say "Worsened", first in FY2019. Latest entry: 2026-11-10.
Nishi-Nippon Financial Holdings moved to the "Worse" side of this theme in 2019, 3 years before the typical company in this theme (2022).
The whole theme swung hardest in 2019: 5 of 9 companies on the "Worse" side.
1 other company's latest entry also says "Worsened".
- 2026-11-10WorsenedResults
「その他有価証券 1,919,680 30,454 △ 2,910 5,244 107,812 77,358 33,364 25,210」
その他有価証券の評価損益は、2026年3月末の評価損益218億74百万円から2026年9月末には198億13百万円へ減少した。 - FY2026WorsenedAnnual report
「As of 31 March 2026, the market risk amount for the Group as a whole was ¥93,466 million (¥75,816 million as of 31 March 2025).」
While management based on BPV, VaR, risk limits and backtesting continued, the market risk amount increased from ¥75,816 million to ¥93,466 million. - 2026-05-12MitigatedRevision to earnings forecast
「その他有価証券評価差額金 △3,550 21,874」
その他有価証券評価差額金は2025年3月末のマイナス35億50百万円から2026年3月末の218億74百万円へ改善した。 - FY2026-H1MitigatedAnnual report
「Valuation difference on available-for-sale securities △3,550 16,233」
The valuation difference on available-for-sale securities improved from negative ¥355 million at the end of March 2025 to ¥1,623.3 million at the end of September 2025. No impairment loss was recognized on securities during the interim consolidated accounting period. - FY2025WorsenedAnnual report
「Valuation difference on available-for-sale securities 43,262 △3,550」
The valuation difference on available-for-sale securities decreased from ¥4,326.2 million at the end of March 2024 to negative ¥355 million at the end of March 2025, reflecting the impact of fluctuations in securities prices in the financial information. - FY2025-H1WorsenedAnnual report
「Valuation difference on available-for-sale securities 43,262 30,761」
The valuation difference on available-for-sale securities decreased from ¥4,326.2 million at the end of March 2024 to ¥3,076.1 million at the end of September 2024. The valuation difference also decreased from ¥6,304.8 million to ¥4,528.4 million, while no impairment loss was recognized on securities during the interim consolidated accounting period. - FY2024-Q3MitigatedAnnual report
「Valuation difference on available-for-sale securities 25,757 31,841 The impairment loss recognized during the cumulative third quarter was ¥79 million on shares.」
The valuation difference on available-for-sale securities recovered from ¥2,575.7 million at the end of March 2023 to ¥3,184.1 million at the end of December 2023. Meanwhile, an impairment loss of ¥79 million on shares was recognized, and the impact of fluctuations in securities prices remains. - FY2024-Q2WorsenedAnnual report
「Valuation difference on available-for-sale securities 25,757 9,631 The impairment loss recognized during the interim consolidated accounting period was ¥72 million on shares.」
The valuation difference on available-for-sale securities decreased from ¥2,575.7 million at the end of March 2023 to ¥963.1 million at the end of September 2023, and an impairment loss of ¥72 million on shares was also recognized. In addition, net interest income for the interim period decreased by ¥480.3 million year on year, while funding costs increased from ¥352.1 million to ¥1,270.9 million. - FY2024-Q1WorsenedAnnual report
「Net interest income for the cumulative first quarter was ¥2,408.8 million in the domestic banking segment and negative ¥174.3 million in the international banking segment, for a total of ¥2,234.5 million, a decrease of ¥296.6 million from the same quarter of the previous year.」
Net interest income decreased by ¥296.6 million year on year, with the international banking segment recording a negative ¥174.3 million. Funding costs also increased from ¥106.4 million in the same period of the previous year to ¥594.8 million, reflecting the impact of changes in the interest-rate environment on earnings. - FY2023WorsenedAnnual report
「As of 31 March 2023, the market risk amount for the Group as a whole was ¥73,872 million (¥69,811 million as of 31 March 2022).」
While management based on BPV, VaR, risk limits and backtesting continued, the market risk amount increased from ¥69,811 million to ¥73,872 million. - FY2023-Q3WorsenedAnnual report
「Total 1,678,333 1,734,539 56,205 Total 1,821,651 1,821,154 △496」
The valuation difference on available-for-sale securities decreased from ¥5,620.5 million at the end of March 2022 to negative ¥496 million at the end of December 2022. The valuation difference was negative, mainly for bonds. Meanwhile, no impairment loss was recognized during the cumulative third quarter. - FY2023-Q1MitigatedAnnual report
「There were no impairment losses for the first quarter of the fiscal year.」
No impairment loss on securities, for which ¥2,056 million had been recognized in the previous consolidated fiscal year, was recognized in the first quarter. The valuation difference on available-for-sale securities decreased from ¥5,620.5 million to ¥3,158.6 million. - FY2022WorsenedAnnual report
「As of 31 March 2022, the market risk amount for the Group as a whole was ¥69,811 million (¥53,172 million as of 31 March 2021).」
While management based on BPV, VaR and other measures continued, the market risk amount increased from ¥53,172 million to ¥69,811 million. The impairment loss recognized on securities was ¥2,056 million, and the valuation difference on available-for-sale securities also decreased. - FY2022-Q3WorsenedAnnual report
「The impairment loss recognized during the cumulative third quarter was ¥2,510 million, comprising ¥2,509 million on shares and ¥1 million on corporate bonds.」
An impairment loss of ¥2,510 million arising from fluctuations in securities prices was recognized during the cumulative third quarter, most of it relating to shares. The valuation difference on available-for-sale securities also decreased from ¥6,523.8 million at the end of March 2021 to ¥6,207.3 million. - FY2022-Q2MaterialisedAnnual report
「The impairment loss recognized during the interim consolidated accounting period was ¥222 million on shares.」
An impairment loss of ¥222 million on shares arising from fluctuations in securities prices was recognized during the interim period. The valuation difference on available-for-sale securities also decreased from ¥6,523.8 million at the end of March 2021 to ¥6,327.3 million. - FY2022-Q1MaterialisedAnnual report
「The impairment loss recognized during the cumulative first quarter was ¥57 million on shares.」
An impairment loss of ¥57 million on shares arising from fluctuations in securities prices was recognized in the first quarter. The valuation difference on available-for-sale securities decreased from ¥6,523.8 million at the end of March 2021 to ¥6,075.3 million. - FY2021WorsenedAnnual report
「As of 31 March 2021, the market risk amount for the Group as a whole was ¥53,172 million (¥30,369 million as of 31 March 2020).」
While management based on BPV, VaR, risk limits and backtesting continued, the market risk amount increased from ¥30,369 million to ¥53,172 million. - FY2021-Q3MitigatedAnnual report
「Valuation difference on available-for-sale securities 47,032 58,300」
The valuation difference on available-for-sale securities increased from ¥4,703.2 million at the end of March 2020 to ¥5,830 million at the end of December 2020, indicating a recovery in the valuation difference. Meanwhile, the impairment loss recognized on securities during the cumulative third quarter was ¥107 million, comprising ¥18 million on shares and ¥88 million on corporate bonds. - FY2021-Q2MaterialisedAnnual report
「The impairment loss recognized during the interim consolidated accounting period was ¥107 million, comprising ¥19 million on shares and ¥88 million on corporate bonds.」
An impairment loss of ¥107 million arising from fluctuations in securities prices was recognized during the interim period. Meanwhile, the valuation difference on available-for-sale securities increased from ¥4,703.2 million at the end of March 2020 to ¥5,558.5 million. - FY2021-Q1MaterialisedAnnual report
「The impairment loss recognized during the cumulative first quarter was ¥88 million on corporate bonds.」
An impairment loss of ¥88 million on corporate bonds was recognized in the first quarter as a loss arising from fluctuations in securities prices. Meanwhile, the valuation difference on available-for-sale securities increased from ¥4,703.2 million at the end of March 2020 to ¥5,313.9 million. - FY2020MaterialisedAnnual report
「In the fiscal year ending March 2020, an impairment loss of ¥1,400 million was recognized on shares held by a banking subsidiary following the decline in the stock market due to the impact of the novel coronavirus and other factors.」
The risk of price fluctuations caused by the decline in the stock market materialized as a ¥1,400 million impairment loss on shares held. - FY2020-Q3WorsenedAnnual report
「Valuation difference on available-for-sale securities 57,200 55,439」
The valuation difference on available-for-sale securities decreased from ¥5,720 million at the end of March 2019 to ¥5,543.9 million at the end of December 2019, reflecting the impact of fluctuations in securities prices in the financial information. - FY2020-Q2WorsenedAnnual report
「Valuation difference on available-for-sale securities 57,200 54,615」
The valuation difference on available-for-sale securities decreased from ¥5,720 million at the end of March 2019 to ¥5,461.5 million at the end of September 2019. The impact of fluctuations in securities prices continued to be reflected in the financial information. - FY2020-Q1WorsenedAnnual report
「Valuation difference on available-for-sale securities 57,200 54,338」
The valuation difference on available-for-sale securities decreased from ¥5,720 million at the end of March 2019 to ¥5,433.8 million at the end of June 2019, reflecting the impact of fluctuations in securities prices in the financial information. - FY2019WorsenedAnnual report
「Valuation difference on other securities 79,474 57,200」
The valuation difference on available-for-sale securities decreased from ¥7,947.4 million at the end of the previous fiscal year to ¥5,720 million, reflecting the impact of fluctuations in stock and bond prices in the financial information. - FY2017RestatedAnnual report
「As interest rates fluctuate amid mismatches in the amounts and maturities of these funds, net interest margins may narrow, potentially adversely affecting the Group's financial condition and performance.」
The risks of fluctuations in interest rates, foreign exchange rates and securities prices are reiterated. - FY2017-Q3First statedAnnual report
「The Group's assets and liabilities consist primarily of loans, securities and deposits, which are its principal businesses, while its main source of revenue is net interest income from investing and raising funds. As interest rates fluctuate amid mismatches in the amounts and maturities of these funds, net interest margins may narrow, potentially adversely affecting the Group's financial condition and performance.」
In addition to interest-rate risk, foreign-exchange risk on foreign-currency-denominated assets and liabilities and price volatility risk on securities are identified as part of the same market-risk category.